Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2014-06-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-013-2763-zPMID 24337596
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype

  2013cited by this paper
• Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.

  2013cited by this paper
• Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta-analysis

  2012cited by this paper
• Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.

  2012cited by this paper
• Estrogen Receptor Negative and Progesterone Receptor Positive Breast Carcinomas—How Frequent are they?

  2011cited by this paper
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

  2011cited by this paper
• A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

  2011cited by this paper
• Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer

  2010cited by this paper
• Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.

  2010cited by this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010influential reference
• Genomic index of sensitivity to endocrine therapy for breast cancer.

  2010cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory.

  2008cited by this paper
• Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

  2008cited by this paper
• Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

  2008cited by this paper
• Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.

  2007cited by this paper
• Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

  2007cited by this paper
• Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

  2007cited by this paper
• Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

  2005cited by this paper
• Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.

  2005cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study

  2000cited by this paper
• Estrogen receptor negative and progesterone receptor positive primary breast cancer: Pathological characteristics and clinical outcome

  1998cited by this paper
• A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

  1989cited by this paper
• Multiple progesterone receptor assays in human breast cancer.

  1984cited by this paper

• CA9+ cancer-associated fibroblasts cooperate with SPP1+ tumor-associated macrophages driving immune resistance in triple-negative breast cancer

  2026cites this paper
• Small molecule inhibitors for treating breast cancer: drug analysis based on the pathogenesis of breast cancer.

  2025cites this paper
• Generalized composite multi-sample tests for high-dimensional data

  2025cites this paper
• Enhancing breast cancer treatment: Evaluating the efficacy of hyaluronic acid-coated tamoxifen-loaded solid lipid nanoparticles on MCF7 cells

  2025cites this paper
• KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavage

  2025cites this paper
• Aromatase inhibitors for the treatment of breast cancer: An overview (2019-2023).

  2024cites this paper
• GSDME-mediated pyroptosis promotes anti-tumor immunity of neoadjuvant chemotherapy in breast cancer

  2024cites this paper
• Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells

  2024cites this paper
• Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy

  2024cites this paper
• An analysis of the prognostic role of reactive oxygen species‐associated genes in breast cancer

  2024cites this paper
• Assessing Reusability of Deep Learning-Based Monotherapy Drug Response Prediction Models Trained with Omics Data

  2024cites this paper
• Differentiating Primary and Recurrent Lesions in Patients with a History of Breast Cancer: A Comprehensive Review

  2024cites this paper
• CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression.

  2024cites this paper
• The mevalonate pathway contributes to breast primary tumorigenesis and lung metastasis

  2024cites this paper
• Single progesterone receptor-positive phenotype has the similar clinicopathological features and outcome as triple-negative subtype in metastatic breast cancer

  2023cites this paper
• Heterogeneous multi-task feature learning with mixed ℓ2,1\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\ell _{2,1}$$

  2023cites this paper
• Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma

  2023cites this paper
• The Biological Significance Of AFF4: Promoting Transcription Elongation, Osteogenic Differentiation and Tumor Progression.

  2023cites this paper
• Annotated Compendium of 102 Breast Cancer Gene-Expression Datasets

  2023cites this paper
• PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer

  2023cites this paper
• Identification of cell subpopulations associated with disease phenotypes from scRNA-seq data using PACSI

  2023cites this paper
• Reusability Report: Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients

  2023cites this paper
• Reusability report: Evaluating reproducibility and reusability of a fine-tuned model to predict drug response in cancer patient samples

  2023cites this paper
• Visualized machine learning models combined with propensity score matching analysis in single PR-positive breast cancer prognosis: a multicenter population-based study.

  2023cites this paper
• A prospective cohort study of clinical characteristics and outcomes in Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer

  2023cites this paper
• Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview.

  2023cites this paper
• Translocon-associated protein subunit SSR3 determines and predicts susceptibility to paclitaxel in breast cancer and glioblastoma.

  2022cites this paper
• Neurogenesis and angiogenesis are associated features of aggressive breast cancer

  2022cites this paper
• Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER−PR+HER2−) breast cancer

  2022cites this paper
• Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC).

  2021cites this paper
• The high methylation level of a novel 151-bp CpG island in the ESR1 gene promoter is associated with a poor breast cancer prognosis

  2021cites this paper
• Progesterone Receptor Signaling in the Breast Tumor Microenvironment.

  2021cites this paper
• Is oestrogen receptor-negative/progesterone receptor-positive (ER−/PR+) a real pathological entity?

  2021cites this paper
• Immunohistochemical and clinicopathologic features of estrogen receptor-negative, progesterone receptor-positive, HER-2 negative breast carcinomas.

  2021cites this paper
• Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival

  2021cites this paper
• Molybdenum Target X-Ray Features and Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 in Invasive Breast Cancer

  2021cites this paper
• High expression levels of centromere protein A plus upregulation of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling pathway affect chemotherapy response and prognosis in patients with breast cancer

  2021cites this paper
• Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms

  2021cites this paper
• MHC Class I Loss in Triple-negative Breast Cancer

  2021cites this paper
• Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype

  2021cites this paper
• Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment

  2021cites this paper
• High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer

  2021influential citation
• Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer

  2021cites this paper
• Negative Estrogen receptors and positive progesterone receptors breast cancers.

  2020cites this paper
• Flexible Data Trimming Improves Performance of Global Machine Learning Methods in Omics-Based Personalized Oncology

  2020cites this paper
• High dimensional model representation of log-likelihood ratio: binary classification with expression data

  2020cites this paper
• G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer

  2020influential citation
• AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors

  2020cites this paper
• Molecular Biological Features of Nottingham Histological Grade 3 Breast Cancers

  2020cites this paper
• Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1

  2020cites this paper
• The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer

  2020cites this paper
• Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer

  2020cites this paper
• Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments

  2020cites this paper
• CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer

  2020cites this paper
• Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

  2020cites this paper
• Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients

  2020cites this paper
• Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer

  2020cites this paper
• Estrogen Receptor-negative/progesterone Receptor-positive and Her-2 Negative Breast Cancer Might No Longer Be Classi�ed as Hormone Receptor Positive Breast Cancer

  2020influential citation
• Estrogen Receptor-negative/progesterone Receptor-positive and Her-2 Negative Breast Cancer Might No Longer Be Classi�ed as Hormone Receptor Positive Breast Cancer

  2020influential citation
• Low infiltration of tumor-associated macrophages in high c-Myb-expressing breast tumors

  2019cites this paper
• FusionLearn: a biomarker selection algorithm on cross-platform data

  2019cites this paper
• Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis

  2019cites this paper
• Gene Expression-Based Predictive Markers for Paclitaxel Treatment in ER+ and ER− Breast Cancer

  2019influential citation
• FLOating-Window Projective Separator (FloWPS): A Data Trimming Tool for Support Vector Machines (SVM) to Improve Robustness of the Classifier

  2019cites this paper
• Flexible Data Trimming for Different Machine Learning Methods in Omics-Based Personalized Oncology

  2019cites this paper
• Correlation‐adjusted regression survival scores for high‐dimensional variable selection

  2018cites this paper
• Differential expression and feature selection in the analysis of multiple omics studies

  2018cites this paper
• Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals

  2018cites this paper
• Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers

  2018cites this paper
• Vav proteins maintain epithelial traits in breast cancer cells using miR-200c-dependent and independent mechanisms

  2018cites this paper
• Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining

  2018cites this paper
• Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?

  2018cites this paper
• Identifying statistically significant combinatorial markers for survival analysis

  2018cites this paper
• Circulating anti‐Müllerian hormone and breast cancer risk: A study in ten prospective cohorts

  2018cites this paper
• Transcriptome evolution from breast epithelial cells to basal-like tumors

  2017cites this paper
• An interaction network approach to study the correlation between endocrine disrupting chemicals and breast cancer.

  2017cites this paper
• Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors

  2017cites this paper
• Angiopoietin pathway gene expression associated with poor breast cancer survival

  2017cites this paper
• Análise da frequência e determinação imuno-histoquímica dos carcinomas mamários receptor de estrogênio negativo e receptor de progesterona positivo

  2017cites this paper
• Prognostic role of progesterone receptor expression in a population-based analysis

  2017cites this paper
• Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors

  2017cites this paper
• Mechanical cue‐induced YAP instructs Skp2‐dependent cell cycle exit and oncogenic signaling

  2017cites this paper
• Overexpression of Uridine-Cytidine Kinase 2 Correlates with Breast Cancer Progression and Poor Prognosis

  2017cites this paper
• Association of long-chain acyl-coenzyme A synthetase 5 expression in human breast cancer by estrogen receptor status and its clinical significance.

  2017cites this paper
• Finding disagreement pathway signatures and constructing an ensemble model for cancer classification

  2017cites this paper
• Variable screening with multiple studies

  2017cites this paper
• Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer

  2017cites this paper
• Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data

  2016cites this paper
• Molecular Classification of Breast Cancer

  2016cites this paper
• Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features

  2016cites this paper
• Family Matters: Collaboration and Conflict Among the Steroid Receptors Raises a Need for Group Therapy.

  2016cites this paper
• Prognostic Significance of Single Progesterone Receptor Positivity

  2015cites this paper
• Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer

  2015cites this paper
• Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

  2015cites this paper
• Co-modulation analysis of gene regulation in breast cancer reveals complex interplay between ESR1 and ERBB2 genes

  2015cites this paper
• Estrogen Receptor and Signal Transducer and Activator of Transcription 3 Expression in Equine Mammary Tumors

  2015cites this paper
• Analysis of the clinical utility of gene expression profiling in relation to conventional prognostic markers in South African patients with breast carcinoma

  2014cites this paper
• Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease

  2014cites this paper